scispace - formally typeset
F

Félix Gutiérrez

Researcher at Universidad Miguel Hernández de Elche

Publications -  321
Citations -  10243

Félix Gutiérrez is an academic researcher from Universidad Miguel Hernández de Elche. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 48, co-authored 302 publications receiving 8638 citations. Previous affiliations of Félix Gutiérrez include Hospital General Universitario Gregorio Marañón & Carlos III Health Institute.

Papers
More filters
Journal ArticleDOI

Factors that carry way the appearance of anxiety during the COVID-19 pandemic

TL;DR: In this article , a literature search was conducted through digital platforms, in which twenty articles published during the years 2020 and 2021 were analyzed, in English and Spanish, related to anxiety during the COVID-19 pandemic, finding that the main factors that had a higher rate of causing anxiety were social isolation and concern about the economy, creating uncertainty about the health emergency being experienced.
Journal ArticleDOI

Pericarditis caused by Mycobacterium africanum: case report

TL;DR: In this article , the first case of tuberculous pericarditis caused by Mycobacterium africanum was reported in a 31-year-old man, native from Senegal, who came to the emergency room with massive perricardial effusion and cardiac tamponade requiring pericardiocentesis.
Journal ArticleDOI

Unplanned pregnancies and social and partner support during pregnancy in Spanish women living with HIV

TL;DR: In this paper , the authors describe prevalence and factors associated with unplanned pregnancies, and social and partner support during pregnancy among women from the Cohort of the Spanish HIV/AIDS Research Network (CoRIS).
Journal ArticleDOI

HIV-1 RNA levels in rectal and seminal compartments after switching to long-acting cabotegravir plus rilpivirine: a longitudinal study.

TL;DR: HIV-1 RNA levels were longitudinally evaluated in 211 rectal and 152 seminal samples from 12 virologically-suppressed participants switching to monthly long-acting cabotegravir plus rilpivirine or continuing with daily dolute gravir-abacavir-lamivudine.